Obalon Therapeutics Inc
OBLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.47M
Close$
$3.55
16.5% upside
Current Fair Value
16.5% upsideUndervalued by 16.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.47 Million |
|---|---|
| Enterprise Value | $-3,300,925.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | -1.24 |
| Outstanding Shares | 0 |
Return
| Return on Equity | -145.78% |
|---|---|
| Return on Assets | -115.09% |
| Return on Invested Capital | -139.72% |
Valuation & Multiples
| P/E Ratio | -0.3 |
|---|---|
| PEG | 0.18 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.33 |
| Enterprise Value to EBIT | 0.29 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Obalon Therapeutics Inc
CEO: Andrew Rasdal